Abstract
Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Infectious Disorders - Drug Targets
Title:Tuberculosis Vaccines: Hopes and Hurdles
Volume: 13 Issue: 5
Author(s): Mohamed J. Ahsan, Shiv K. Garg, Bharat Vashistha and Piush Sharma
Affiliation:
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Abstract: Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Export Options
About this article
Cite this article as:
Ahsan J. Mohamed, Garg K. Shiv, Vashistha Bharat and Sharma Piush, Tuberculosis Vaccines: Hopes and Hurdles, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526513666131201125513
DOI https://dx.doi.org/10.2174/1871526513666131201125513 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomedical Applications of Natural Polymers for Drug Delivery
Current Organic Chemistry Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety In Silico Assessment of Adverse Effects of a Large Set of 6-Fluoroquinolones Obtained from a Study of Tuberculosis Chemotherapy
Current Drug Safety The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Development and Optimization of Inhalable Levofloxacin Nanoparticles for The Treatment of Tuberculosis
Current Drug Delivery Host-Pathogen Interactions in Latent Mycobacterium tuberculosis Infection: Identification of New Targets for Tuberculosis Intervention
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Lectin Techniques for Glycoproteomics
Current Proteomics Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Graphical Abstracts
Letters in Drug Design & Discovery Structure Based Design of CYP51 Inhibitors
Current Topics in Medicinal Chemistry The Effects of Melatonin on the Oxidative Stress and Duration of Atrial Fibrillation after Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets A Role of the 9-Aminoacridines and their Conjugates in a Life Science
Current Protein & Peptide Science New Heterocyclic Hydrazones in the Search for Antitubercular Agents: Synthesis and In Vitro Evaluations
Letters in Drug Design & Discovery CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
Endocrine, Metabolic & Immune Disorders - Drug Targets Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry